Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Association of Xrcc2 Rs3218536 Polymorphism With Susceptibility of Breast and Ovarian Cancer: A Systematic Review and Meta-Analysis Publisher



Kamali M1, 2 ; Hamadani S1, 2 ; Neamatzadeh H3, 4 ; Mazaheri M3, 4 ; Shehneh MZ3, 4 ; Gilani MM1, 2 ; Haghighi F5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Perinatology, School of Medicine, Tehran University Medical of Sciences, Tehran, Iran
  2. 2. Maternal-Fetal and Neonatal Research Center, Tehran University Medical of Sciences, Tehran, Iran
  3. 3. Mother and Newborn Health Research Center, Yazd, Iran
  4. 4. Department of Medical Genetics, International Campus, Yazd, Iran
  5. 5. Department of Gynecology and Obstetrics, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

Source: Asian Pacific Journal of Cancer Prevention Published:2017


Abstract

Background: Previous studies have investigated the association of X-Ray Repair Cross-Complementing Group 2 (XRCC2) rs3218536 polymorphism with breast and ovarian cancer. However, this association remains conflicting. Therefore, we have performed the current systematic review and meta-analysis to clarify the association between XRCC2 rs3218536 polymorphism with risk of breast and ovarian cancer. Methods: We conducted a search in PubMed, Google Scholar and ISI Web of Science to select relevant studies on the association of XRCC2 rs3218536 polymorphism with breast and ovarian cancer susceptibility. We calculated the odds ratios (OR) and 95% confidence intervals (CI) for five genetic contrasts. In addition, a stratified analysis was conducted cancer type, ethnicity and HWE status. Results: A total of 17 studies with 5694 cases and 6450 controls for breast cancer and nine case-control studies with 4464 cases and 6353 controls for ovarian cancer were identified for the analysis of the association with XRCC2 rs3218536 polymorphism. The pooled ORs revealed that XRCC2 rs3218536 polymorphism was associated with breast cancer under the heterozygote contrast (AG vs. GG: OR = 0.929, 95% CI = 0.873-0.987, p=0.018) and ovarian cancer under dominant contrast (AA+AG vs. GG: OR = 0.725, 95% CI = 0.537-0.979, p=0.036) in the overall population. The stratified analysis indicated a significant association of XRCC2 rs3218536 polymorphism with breast and ovarian cancer risk among Caucasians. Conclusion: Inconsistent with previous meta-analysis, this meta-analysis shows that the XRCC2 rs3218536 polymorphism was associated with breast and ovarian cancer risk in overall population, especially among Caucasians.
Experts (# of related papers)
Other Related Docs
38. The Association Between Maternal Smoking and Hyperemesis Gravidarum: A Meta-Analysis, Journal of Maternal-Fetal and Neonatal Medicine (2017)
43. Sleep Quality in Iranian Hemodialysis Patients: A Systematic Review and Meta-Analysis, Iranian Journal of Nursing and Midwifery Research (2019)